<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00085423</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000370788</org_study_id>
    <secondary_id>P30CA023108</secondary_id>
    <secondary_id>DMS-0320</secondary_id>
    <secondary_id>DMS-16531</secondary_id>
    <nct_id>NCT00085423</nct_id>
    <nct_alias>NCT00225771</nct_alias>
  </id_info>
  <brief_title>Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma</brief_title>
  <official_title>High Dose Interleukin-2 (IL-2) Therapy In &quot;Lymphodepleted Primed&quot; Patients With Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide and fludarabine, work in
      different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2
      may stimulate a person's white blood cells to kill tumor cells and may help a person's immune
      system recover from the side effects of chemotherapy.

      PURPOSE: This phase II trial is studying how well giving cyclophosphamide and fludarabine
      together with high-dose interleukin-2 works in treating patients with metastatic melanoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the objective response rate in lymphodepleted patients with metastatic
           melanoma treated with cyclophosphamide, fludarabine, and high-dose interleukin-2.

        -  Determine the feasibility of this regimen in these patients.

      Secondary

        -  Determine the quality and quantity of lymphocyte recovery in these patients during and
           after treatment with this regimen.

        -  Determine time to disease progression and survival in patients treated with this
           regimen.

      OUTLINE: This is an open-label, multicenter study.

      Patients receive lymphodepleting therapy comprising cyclophosphamide IV over 1 hour on days 1
      and 2 and fludarabine IV over 30 minutes on days 3-7. Patients then receive high-dose
      interleukin-2 IV every 8 hours (14 doses) on days 8-12 and 22-26. Patients also receive
      sargramostim (GM-CSF) subcutaneously beginning on day 8 and continuing until blood counts
      recover. Treatment continues in the absence of disease progression or unacceptable toxicity.

      Patients are followed every 3 months.

      PROJECTED ACCRUAL: A total of 18-33 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of partiCIPANTS WITH OBJECTIVE RESPONSE AS MEASURED BY RECIST</measure>
    <time_frame>Response at 12 weeks</time_frame>
    <description>Objective response as measured by radiological and physical examination using RECIST criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Lymphocyte Recovery as Measured by Blood Count</measure>
    <time_frame>on days 1-15, weekly for 2 weeks, and then every 2-3 months</time_frame>
    <description>Lymphocyte recovery to a greater than 1000 cells/mcL was determined by differential peripheral blood cell counts on sequential days as noted in time frame.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression as Measured by RECIST</measure>
    <time_frame>From date of randomization until the first date of documented progression or date of death from any cause, which ever came first, assessed up till 100 months</time_frame>
    <description>Clinical outcome used the National Cancer Institute's Response Evaluation Criteria in Solid Tumors (RECIST)1.0.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Melanoma (Skin)</condition>
  <arm_group>
    <arm_group_label>IL-2, CTX, fludarabine, GM-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aldesleukin (IL-2), cyclophosphamide, fludarabine phosphate, sargramostim</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
    <description>‡Interleukin-2 (aldesleukin) IV (600,000 U/kg; Chiron, Emeryville, CA): two 5-day courses on days 8 and 22. Interleukin-2 was given over 15 minutes every 8 hours. Goal is 14 doses/5-day course</description>
    <arm_group_label>IL-2, CTX, fludarabine, GM-CSF</arm_group_label>
    <other_name>Aldesleukin; IL-2; HD IL-2; Interleukin-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
    <description>GM-CSF was given subcutaneously daily from day 8 until absolute granulocyte count exceeds 5,000 cells/mL for 2 consecutive days.</description>
    <arm_group_label>IL-2, CTX, fludarabine, GM-CSF</arm_group_label>
    <other_name>GM-CSF; granulocyte-macrophage colony-stimulating factor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Cyclophosphamide (60 mg/kg/d; Baxter, Deerfield, IL) intravenously (IV) for 2 days with sodium 2- mercaptoethanesulfonate (Mesna; Sicor, Irvine, CA) at 20% of cyclophosphamide dose IV 15 minutes before and 40% of the cyclophosphamide dose orally at 2 and 6 hours after the initiation of chemotherapy.</description>
    <arm_group_label>IL-2, CTX, fludarabine, GM-CSF</arm_group_label>
    <other_name>cyclophosphamide,Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>Fludarabine IV (25 mg/M2/day)-five daily doses from Day 3</description>
    <arm_group_label>IL-2, CTX, fludarabine, GM-CSF</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed melanoma

          -  Metastatic disease

          -  Measurable disease

          -  No history of brain metastases

          -  Over 18

          -  Karnofsky 60-100%

          -  Life expectancy At least 12 weeks

          -  Hematopoietic

          -  Absolute neutrophil count ≥ 1,000/mm^3

          -  Platelet count ≥ 75,000/mm^3

          -  Hemoglobin ≥ 8.5 g/dL

          -  aspartate aminotransferase ≤ 2 times upper limit of normal (ULN) (5 times ULN if liver
             metastases are present)

          -  Bilirubin ≤ 2 times ULN (except for patients with Gilbert's syndrome)

          -  Hepatitis B and C negative

          -  Creatinine ≤ 2.0 times ULN

          -  Creatinine clearance ≥ 50 mL/min

          -  Cardiovascular

          -  Ejection fraction ≥ 50%

          -  No evidence of congestive heart failure

          -  No symptoms of coronary artery disease

          -  No serious cardiac arrhythmias

          -  No myocardial infarction within the past 6 months

          -  Cardiac stress test negative or of low probability for patients &gt; 40 years of age OR
             who have had prior myocardial infarction &gt; 6 months ago

          -  Pulmonary Forced expiratory volume 1 ≥ 2.0 liters OR at least 75% of predicted for
             height and age

          -  Diffusing capacity of lung for carbon monoxide ≥ 60%

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  HIV negative

        Exclusion Criteria:

          -  No uncontrolled diabetes

          -  No history of autoimmune disease

          -  No active infection

          -  No other concurrent significant illness that would preclude study participation

          -  No other malignancy within the past 5 years except nonmelanoma skin cancer or
             non-invasive cancer (e.g., carcinoma in situ of the cervix, superficial bladder cancer
             without local recurrence, or carcinoma in situ of the breast)

          -  At least 4 weeks since prior immunotherapy and recovered

          -  No other concurrent anticancer biologic agents

          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered

          -  No concurrent chemotherapy

          -  At least 4 weeks since prior steroid therapy

          -  No concurrent corticosteroids

          -  At least 4 weeks since prior radiotherapy and recovered

          -  No concurrent radiotherapy

          -  At least 4 weeks since prior surgery and recovered

          -  No concurrent immunosuppressive therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc S. Ernstoff, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Norris Cotton Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756-0002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Gunturu KS, Meehan KR, Mackenzie TA, Crocenzi TS, McDermott D, Usherwood EJ, Margolin KA, Crosby NA, Atkins MB, Turk MJ, Ahonen C, Fuse S, Clark JI, Fisher JL, Noelle RJ, Ernstoff MS. Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recovery. J Clin Oncol. 2010 Mar 1;28(7):1196-202. doi: 10.1200/JCO.2009.24.8153. Epub 2010 Feb 1.</citation>
    <PMID>20124177</PMID>
  </results_reference>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2004</study_first_submitted>
  <study_first_submitted_qc>June 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2004</study_first_posted>
  <results_first_submitted>January 26, 2012</results_first_submitted>
  <results_first_submitted_qc>April 9, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 10, 2013</results_first_posted>
  <last_update_submitted>April 9, 2013</last_update_submitted>
  <last_update_submitted_qc>April 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>recruitment was open from February 2004 to December 2008.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Lymphodepleting Chemotherapy + High Dose Interleukin-2</title>
          <description>Lymphodepleting chemotherapy + high dose interleukin-2:
Intravenous cyclophosphamide (60 mg/kg, days 1 and 2) and fludarabine (25 mg/m(2), day 3 through 7) followed by two 5-day courses of intravenous high-dose bolus IL-2 (600,000 U/kg; days 8 through 12 and 21 through 25). Granulocyte-macrophage colony-stimulating factor, GM-CSF, (250 microg/m(2)/d beginning day 8) was given until granulocyte recovery.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>screen failure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lymphodepleting Chemotherapy + High Dose IL-2</title>
          <description>intravenous cyclophosphamide (60 mg/kg, days 1 and 2) and fludarabine (25 mg/m(2), day 3 through 7) followed by two 5-day courses of intravenous high-dose bolus IL-2 (600,000 U/kg; days 8 through 12 and 21 through 25). GM-CSF (250 microg/m(2)/d beginning day 8) was given until granulocyte recovery.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of partiCIPANTS WITH OBJECTIVE RESPONSE AS MEASURED BY RECIST</title>
        <description>Objective response as measured by radiological and physical examination using RECIST criteria.</description>
        <time_frame>Response at 12 weeks</time_frame>
        <population>Response was determined by physical examination and radiologic testing. Percent of the total number of patients treated was calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>all patients are treated with lymphodepleting chemotherapy and highdose IL-2 and GM-CSF.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of partiCIPANTS WITH OBJECTIVE RESPONSE AS MEASURED BY RECIST</title>
          <description>Objective response as measured by radiological and physical examination using RECIST criteria.</description>
          <population>Response was determined by physical examination and radiologic testing. Percent of the total number of patients treated was calculated.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Lymphocyte Recovery as Measured by Blood Count</title>
        <description>Lymphocyte recovery to a greater than 1000 cells/mcL was determined by differential peripheral blood cell counts on sequential days as noted in time frame.</description>
        <time_frame>on days 1-15, weekly for 2 weeks, and then every 2-3 months</time_frame>
        <population>each patient's differential blood counts were used to determine the time of recovery to the lower limit of normal lymphocytes in the peripheral blood.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>all patients are treated with lymphodepleting chemotherapy and highdose IL-2 and GM-CSF.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Lymphocyte Recovery as Measured by Blood Count</title>
          <description>Lymphocyte recovery to a greater than 1000 cells/mcL was determined by differential peripheral blood cell counts on sequential days as noted in time frame.</description>
          <population>each patient's differential blood counts were used to determine the time of recovery to the lower limit of normal lymphocytes in the peripheral blood.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="1000" upper_limit="4000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression as Measured by RECIST</title>
        <description>Clinical outcome used the National Cancer Institute’s Response Evaluation Criteria in Solid Tumors (RECIST)1.0.</description>
        <time_frame>From date of randomization until the first date of documented progression or date of death from any cause, which ever came first, assessed up till 100 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>all patients are treated with lymphodepleting chemotherapy and highdose IL-2 and GM-CSF.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression as Measured by RECIST</title>
          <description>Clinical outcome used the National Cancer Institute’s Response Evaluation Criteria in Solid Tumors (RECIST)1.0.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".3" lower_limit=".2" upper_limit=".4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
          <description>all patients are treated with lymphodepleting chemotherapy and highdose IL-2 and GM-CSF.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>3</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <description>8 patients required blood transfusion</description>
                <counts group_id="E1" events="18" subjects_affected="8" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>thrombocytopenia</sub_title>
                <description>4 patients required platelet transfusion</description>
                <counts group_id="E1" events="18" subjects_affected="4" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This was the first stage of a two-stage phase II study and continuation to next stage required 4 of 18 particpant having an objective response. Only 3 objective responses were noted and the study was terminated at stage 1.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Marc Ernstoff</name_or_title>
      <organization>Dartmouth-Hitchcock</organization>
      <phone>603 650 5534</phone>
      <email>marc.s.ernstoff@hitchcock.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

